Avidin Ltd. and the Biological Research Centre of the Hungarian Academy of Sciences started a consortium for the project: “Establishment of tumorous and central nervous system diseases models and developing novel drug candidates”. The project was successfully closed in June 2014 and the total cost was 258 000 000 HUF, including 182 000 000 HUF non-refundable subsidy.
In 1st of September, 2013 Avidin has started an FP7 grant “XENOISLET” (Project full title: “Macroencapsulated Porcine Pancreatic Islets to cure Diabetes Mellitus type 1/2”). The main objective of the project is to undertake specific final steps that will enable successful transplantation of pig insulin-producing cells into human T1DM patients by using alginate macroencapsulation and/or pig transgenesis.
Meet AVIDIN in Chicago at the BIO International Convention between 22-25 April 2013. Our CEO and Head of International Relations are looking forward to meet you during the conference to explore possible synergies. Schedule a meeting in the parntering system and meet us at Booth 0601.
Avidin successfully finished its service capacity development project to test anti-inflammatory compounds by using traditional techniques (measurements of enzymes and cytokines) as well as up-to date methods (focused gene expression profiling and in vivo imaging) in the frame of a research grant (GOP-1.3.1-10B-2010-0016) financed by the Hungarian National Development Agency.
BioEurope ConventionMeet AVIDIN in Vienna at the BioEurope Convention between 4-6 November 2013.Our CEO and Head of International Relations are looking forward to meet you during the conference to explore possible synergies. Schedule a meeting in the parntering system and meet us at the Hungarian Booth.
Avidin has contracted with Sino Biologicals Inc., to represent the Chinese company in Hungary. Sino Biological Inc. is quickly becoming one of the leading global biological solution specialists.
Avidin’s grant proposal entitled “Development of preclinical services for testing anti-inflammatory drugs” won 150,000 EUR support from the European Regional Development Fund (ERDF) and the Hungarian Government in the GOP-1.3.1-10/B call.
Avidin has succeeded in developing anticancer lead compound, Ac-929C against malignant glioma. The new thalidomide analog has been submitted to a patent application in December, 2010.
- Page 1 of 2